Matrix Metalloproteinase-10 Is Required for Lung Cancer Stem Cell Maintenance, Tumor Initiation and Metastatic Potential by Justilien, Verline et al.
Matrix Metalloproteinase-10 Is Required for Lung Cancer
Stem Cell Maintenance, Tumor Initiation and Metastatic
Potential
Verline Justilien
., Roderick P. Regala
., I-Chu Tseng, Michael P. Walsh, Jyotica Batra, Evette S. Radisky,
Nicole R. Murray, Alan P. Fields*
Department of Cancer Biology, Mayo Clinic College of Medicine, Jacksonville, Florida, United States of America
Abstract
Matrix metalloproteinases (Mmps) stimulate tumor invasion and metastasis by degrading the extracellular matrix. Here we
reveal an unexpected role for Mmp10 (stromelysin 2) in the maintenance and tumorigenicity of mouse lung cancer stem-
like cells (CSC). Mmp10 is highly expressed in oncosphere cultures enriched in CSCs and RNAi-mediated knockdown of
Mmp10 leads to a loss of stem cell marker gene expression and inhibition of oncosphere growth, clonal expansion, and
transformed growth in vitro. Interestingly, clonal expansion of Mmp10 deficient oncospheres can be restored by addition of
exogenous Mmp10 protein to the culture medium, demonstrating a direct role for Mmp10 in the proliferation of these cells.
Oncospheres exhibit enhanced tumor-initiating and metastatic activity when injected orthotopically into syngeneic mice,
whereas Mmp10-deficient cultures show a severe defect in tumor initiation. Conversely, oncospheres implanted into
syngeneic non-transgenic or Mmp10
2/2 mice show no significant difference in tumor initiation, growth or metastasis,
demonstrating the importance of Mmp10 produced by cancer cells rather than the tumor microenvironment in lung tumor
initiation and maintenance. Analysis of gene expression data from human cancers reveals a strong positive correlation
between tumor Mmp10 expression and metastatic behavior in many human tumor types. Thus, Mmp10 is required for
maintenance of a highly tumorigenic, cancer-initiating, metastatic stem-like cell population in lung cancer. Our data
demonstrate for the first time that Mmp10 is a critical lung cancer stem cell gene and novel therapeutic target for lung
cancer stem cells.
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Introduction
Non-small cell lung cancer (NSCLC) is the leading cause of
cancer death in the United States [1]. Outcome for NSCLC
patients remains poor, underscoring the need to identify more
effective means of prevention, diagnosis, and treatment. Tumors
contain subpopulations of cells exhibiting stem-like characteristics
that drive pathogenesis [2,3,4]. These cancer-initiating or cancer
stem cells (CSCs) exhibit self-renewal, tumor-initiating activity,
clonal expansion as ‘‘oncospheres’’, the ability to support tumor
maintenance and metastasis, and to differentiate into the
transiently-amplifying cells comprising the bulk tumor [2,4,5,6].
CSCs share molecular features with embryonic stem cells,
including expression of aldehyde dehydrogenase (Aldh) [7], and
stem cell markers such as CD133 [8,9], Nanog [10], Oct4 [10],
Sox2 [11] and Notch receptors [12]. CSCs have been described in
many forms of human cancer including lung cancers [9,13]. The
central role of CSCs in tumorigenesis indicates that these cells
must be targeted therapeutically to achieve effective cancer
treatment.
Mmps have been implicated in lung tumor proliferation,
invasion, and metastasis [14]. The stromelysin subfamily
[stromelysin 1 (Mmp3), 2 (Mmp10) and 3 (Mmp11)] is often
overexpressed in NSCLC [15,16,17,18,19]. Interestingly,
Mmp10 is highly expressed in NSCLC tumors but not tumor-
associated stromal cells, whereas Mmp3 and Mmp11 are
expressed predominantly in stroma [17,19]. We recently
demonstrated that Mmp10 is required for transformed growth
and invasion of human NSCLC cells in vitro [19], is induced in
bronchio-alveolar stem cells (BASCs) transformed by oncogenic
Kras [20], and promotes Kras-mediated lung tumorigenesis in vivo
[21]. Mmp10-deficient mice exhibit a block in Kras-and urethane-
induced tumor formation, an effect that correlates with an
inability of Mmp10-deficient BASCs to expand and undergo
transformation in response to urethane or Kras [21]. Thus,
Mmp10 mediates tumor initiation through control of tumor-
initiating cell (BASC) expansion.
PLoS ONE | www.plosone.org 1 April 2012 | Volume 7 | Issue 4 | e35040Here, we assess the role of Mmp10 in the maintenance and
tumorigenic potential of fully-transformed mouse lung CSCs.
Cultures enriched in CSCs from mouse lung adenocarcinoma cells
express elevated Mmp10, Nanog, Aldh1, CD133, Notch3,
Notch4, Hey1 and Hey2. These cultures exhibit increased
anchorage-independent growth in vitro, and enhanced tumor
initiation, growth and metastatic spread as orthotopic tumors in
syngeneic mice. These stem-like properties require expression of
Mmp10 in tumor cells but not in tumor-associated stroma. Our
results indicate that Mmp10 is an attractive candidate for the
development of mechanism-based therapy targeting highly
tumorigenic lung CSCs.
Results
Mouse lung oncospheres express elevated Mmp10 and
Mmp10-dependent stem-like properties
Mmp10 is highly induced in tumor-initiating lung bronchio-
alveolar stem cells (BASCs) upon activation of oncogenic Kras [20].
Furthermore, Mmp10-deficient mice exhibit decreased Kras-
mediated lung tumor formation and a loss of Kras-mediated
BASC expansion in vitro and in vivo [21]. To directly explore the
importance of Mmp10 in lung CSC biology, we analyzed mouse
CMT167 cells, a highly tumorigenic, metastatic cell line derived
from a spontaneous alveolar lung adenocarcinoma in a C57BL/6
mouse [22,23]. DNA sequencing revealed that CMT167 cells
harbor an activating Kras
G12V mutation (Figure 1A), making it an
ideal cellular model to study Mmp10 in mutant Kras lung CSCs. In
contrast to CMT167 cells grown in adherent culture (Figure 1B,
left), cells grown in defined stem cell medium in low-adherence
plates grow as oncospheres (Figure 1B, middle) reminiscent of
CSC cultures from human lung cancer cell lines [13]. These
oncospheres redifferentiate when returned to adherent culture,
exhibiting morphology comparable to parental cells (Figure 1B,
right). CMT167 oncosphere cultures exhibit a ,8-fold increase
in anchorage-independent colony formation compared to parental
cells (Figure 1C), consistent with the enhanced tumorigenic
properties of CSCs [13]. Enhanced colony formation is largely lost
when these cells are allowed to redifferentiate by returning them to
adherent culture (Figure 1C). Similar results were obtained using
a second mouse lung adenocarcinoma cell line, the Lewis Lung
Carcinoma (LLC) (Figure S1A and B). LLC cells grown as
oncospheres in stem cell culture exhibit enhanced anchorage-
independent colony formation, but lose these properties when
returned to adherent culture. These results demonstrate that our
oncosphere cultures are enriched in cancer stem-like cells.
To further characterize our oncosphere cultures, we assessed
them for expression of well-characterized stem cell-associated
genes. QPCR revealed that CMT167 oncosphere cultures express
elevated mRNA for many genes associated with the stem cell
phenotype [24] including Nanog, Aldh1, CD133, Notch3,
Notch4, Hey1 and Hey2 (Figure 2A). Strikingly, these cultures
also express elevated Mmp10 mRNA (Figure 2A), but no increase
in Mmp2, Mmp7, Mmp9, Mmp11, Mmp12 or Mmp14, other
Mmp species commonly linked to lung cancer (Figure 2A). As
expected, oncosphere cultures exhibit a loss of stem cell markers
and Mmp10 expression when allowed to redifferentiate in
adherent culture (Figure 2B). A similar pattern of stem cell
marker expression was observed in oncosphere cultures from LLC
cells, including a dramatic increase in MMP10, indicating that
these changes are not unique to CMT167 oncospheres (Figur-
e S1C). CMT167 oncosphere cultures secrete elevated Mmp10
protein into the medium compared to parental or redifferentiated
cultures (Figure 2C), demonstrating the functional significance of
elevated Mmp10 expression in these cultures. CD133 and Notch4
are two highly selective surface markers expressed on other lung
CSCs [9,10,25]. Therefore, we assessed the expression of these
markers in CMT167 parental, oncosphere and redifferentiated
oncosphere cultures by flow cytometry (Figure 2D). Parental cell
cultures contain ,8% CD133
+/Notch4
+ cells. In contrast,
oncosphere cultures contain ,38% CD133
+/Notch4
+ cells and
redifferentiated cultures ,6% CD133
+/Notch4
+ cells. These
results are consistent with the prevalence of CSCs in other lung
cancer cell lines [9,10,25,26], indicating that these are selective
markers for CSC-enriched cultures.
Since oncospheres express elevated Mmp10, we next assessed
whether Mmp10 is important for their maintenance and growth.
Three RNAi lentiviruses targeting mouse Mmp10 RNA were
identified that inhibit Mmp10 expression (Figure S2A and B).
Each Mmp10 knockdown virus caused a commensurate inhibition
of anchorage-independent growth compared to non-target (NT)
RNAi control cells (Figure S2C). The most effective Mmp10
RNAi construct (#3) was used to elicit efficient knockdown of
Mmp10 mRNA in both parental and oncosphere cultures
(Figure 3A). Mmp10 knockdown caused an inhibition of
transformed growth (Figure 3B), and a loss in expression of
Nanog, Aldh1, Cd133, Notch3 and 4, Hey1 and 2, and Mmp10
(Figure 3C). Similar results were obtained in LLC oncosphere
cultures in which MMP10 was knocked down by RNAi
(Figure S3A–C). Mmp10 RNAi oncosphere cultures also exhib-
ited a decrease in CD133
+/Notch4
+ cells compared to NT RNAi
oncosphere cultures (Figure 3D). Interestingly, Mmp10 knock-
down also caused a decrease in CD133
+/Notch4
+ cells in parental
cultures (from ,11% to ,5%) (Figure 3D), indicating that
Mmp10 is important for the maintenance of a CSC population
within parental cultures.
We next determined whether Mmp10 is important for clonal
expansion of oncospheres, a well-defined characteristic of CSCs.
Single Mmp10 RNAi- and NT RNAi oncosphere cells were plated
in individual wells of low-adherent tissue culture plates and
allowed to clonally expand. Virtually all NT RNAi cells expand
into large oncospheres over a 15 day period (Figure 4A, upper),
whereas the majority of Mmp10 RNAi cells remain as single cells
(Figure 4A, lower). Similar results were obtained in LLC
oncosphere cultures (Figure S3D). The decreased clonal expan-
sion of CMT167 oncospheres was due to genetic loss of Mmp10
since addition of recombinant Mmp10 to the culture medium
restored clonal expansion of Mmp10 RNAi cells (Figure 4A,
lower). Quantitation confirmed that NT RNAi oncospheres grow
significantly larger than Mmp10 RNAi oncospheres, and addition
of recombinant Mmp10 restores growth of Mmp10 RNAi cells to
that comparable to NT RNAi cells while having no significant
effect on NT RNAi cells (Figure 4B). Exogenous Mmp10 also led
to re-expression of CD133 and Notch4 on Mmp10 RNAi cells
(Figure 4C), and re-expression of stem cell markers (Nanog,
Aldh1, Cd133, Notch3, Notch4 and Hey2) (Figure S4A). The
decreased clonal growth of Mmp10 RNAi oncospheres is not due
to a loss of cell viability, since these cells proliferate at a rate
indistinguishable from NT RNAi oncospheres when placed back
into adherent culture (Figure S4B).
Oncosphere cultures exhibit Mmp10-dependent tumor-
initiating activity in vivo
We next evaluated the tumor-initiating activity of oncosphere
and parental cultures by orthotopic injection into the left lobe of
the lung of syngeneic mice. Initial experiments determined that
injection of 100,000 parental CMT167/luc cells was required to
establish orthotopic tumors whereas injection of as few as 1,000
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gave tumors. Injection of 1,000 NT RNAi CMT167/luc
oncosphere cells led to large tumors whereas injection of 1,000
parental NT RNAi CMT167/luc cells or Mmp10 RNAi
CMT167/luc oncosphere cells failed to produce large tumors as
determined by live imaging of bioluminescence (Figure 5A).
Pathological examination of lung tissues at the time of sacrifice
demonstrated that tumor take was 100% for NT RNAi CMT167/
luc oncosphere cells (9/9) with an average tumor size of 3.63 +/
2.35 mm
2, but only 45% tumor take for parental NT RNAi
CMT167/luc cells (5/11) with an average tumor size of 0.42 +/
2.06 mm
2, and 27% tumor take for Mmp10 RNAi CMT167/luc
oncosphere cells (3/11) with an average tumor size of 0.36 +/
2.09 mm
2. These data validate our in vivo bioluminescence
measurements and demonstrate that Mmp10 plays a critical role
in the tumor-initiating activity and growth of CMT167/luc
oncosphere cells. Interestingly, Mmp10 knockdown in parental
cells also leads to a loss of tumor formation in vivo (Figure S5A),
indicating that Mmp10 is important for the tumor-initiating
activity of a CSC-like cell population present in parental cell
cultures. NT RNAi CMT167/luc oncosphere cultures also
generated numerous metastases to the right lobes of the lung
whereas parental NT RNAi CMT167/luc cell cultures exhibited
far fewer metastases and Mmp10 RNAi CMT167/luc oncosphere
cultures fewer still (Figure S5B), suggesting a role for Mmp10 in
metastatic potential, a property ascribed to lung CSCs. Thus,
Mmp10 is important for the enhanced tumorigenic potential
observed in oncosphere cultures.
Tumorigenicity is independent of Mmp10 in the tumor
microenvironment
The effects of Mmp10 in CMT167 cells in vitro are cell
autonomous. However, we cannot rule out a role for Mmp10
produced by tumor-associated epithelial, stromal and/or immune
cells in our orthotopic tumor studies. To address this issue, we
injected 1,000 cells from NT RNAi CMT167/luc oncosphere
cultures into either Ntg or Mmp10
2/2 mice. No significant
differences in tumor growth (Figure 5B), primary tumor size
(Figure 5C) or metastases (Figure 5D) were seen in Ntg and
Mmp10
2/2 recipient mice, indicating that Mmp10 expressed by
oncospheres, but not from Mmp10 produced by other tumor-
associated cells, is critical for tumor formation. We previously
demonstrated that Mmp10 is expressed in vanishingly low levels in
the lung epithelium, but is highly induced in BASCs upon
activation of oncogenic Kras [20]. Thus, tumor cells are the major
source of Mmp10 in the lungs of tumor-bearing mice.
Oncosphere cultures differentiate into bulk tumor cells
after orthotopic injection
CSCs initiate and maintain tumors by maintaining a CSC
population and differentiating into transiently-amplifying cells that
make up the bulk tumor. To assess the fate of CMT167
oncospheres after orthotropic tumor formation, we isolated tumor
cells from orthotopic tumors derived from these cultures and
analyzed them for CD133
+/Notch4
+ cells (Figure 6). At the time
of injection, the oncosphere cultures showed significant enrich-
ment in CD133
+/Notch4
+ cells (,36%) (Figure 6A). In contrast,
tumor cells isolated from orthotopic tumors consisted of ,11%
Figure 1. Enrichment of CMT167 cancer stem cells. A) CMT167 cells harbor an activating Kras
G12V mutation. DNA sequence chromatogram of
Kras allele in CMT167 cells reveals a codon 12 mutation from glycine to valine (Kras
G12V)( red arrow). B) Phase contrast photomicrographs of parental
adherent CMT167 cells (left panel), CMT167 oncospheres in stem cell culture (middle panel) and redifferentiated oncosphere cells after return to
adherent culture (right panel). C) CMT167 oncosphere cultures exhibit enhanced anchorage-independent growth. Mean fold-change from CMT167
parental cells +/2SEM. n=5, *p,0.00001; **p,0.00001.
doi:10.1371/journal.pone.0035040.g001
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+/Notch4
+ cells, consistent with parental CMT167 cells (Figure 6B). These data indicate that oncosphere cultures
Figure 2. Molecular and functional characterization of CMT167 oncosphere cultures. A) Expression of cancer stem cell markers in CMT167
parental and oncosphere cultures. QPCR of cancer stem cell-associated genes; *p,0.05. B) QPCR for stem cell markers in parental, oncosphere and
redifferentiated oncosphere cultures. Fold of parental cells +/2SEM, n=3; *p,0.05. C) CMT167 oncosphere cultures secrete elevated Mmp10 protein.
ELISA of culture supernatants from parental, oncosphere and redifferentiated CMT167 oncosphere cultures. Mean +/2 SEM. n=3, *p,1610
28
parental vs. oncospheres; **p,2610
28 oncospheres vs. redifferentiated oncospheres. D) Flow cytometry of CMT167 parental, oncosphere and
redifferentiated oncosphere cultures for CD133 and Notch4.
doi:10.1371/journal.pone.0035040.g002
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+/Notch4
+ stem-like cells, and
also differentiate into transiently-amplifying tumor cells in vivo.
We also explored the distribution of CMT167 oncosphere cells in
orthotopic tumors by immunohistochemistry for Mmp10 and
Notch4 (Figure 6C). Primary tumors derived from oncospheres
exhibited slightly elevated Mmp10 staining with darker Mmp10
staining in areas where the tumor interacts with surrounding
stroma. Tumor-associated stroma and normal lung epithelium
stain negative for Mmp10, consistent with the paucity of Mmp10
expression in normal lung epithelium [20]. Notch4 staining
exhibited a similar pattern, indicating co-expression of Mmp10
and Notch4 in tumor cells at the interface of the tumor and
surrounding stroma (Figure 6C, upper).
Mmp10 expression is associated with metastasis of lung
cancer cells
Recent evidence indicates that CSCs reside in pre-metastatic
niches responsible for metastatic tumor spread. Given the
association of stemness and metastatic potential, we assessed the
expression of Mmp10 and Notch4 in metastatic lesions from
tumors derived from oncospheres. Interestingly, both Mmp10 and
Notch4 staining was intense and uniform in metastatic lesions
(Figure 6C, lower), indicating that these lesions are enriched in
Mmp10-Notch4 double positive CSCs. A similar association of
Mmp10 expression with metastatic lesions in human cancers was
observed when we analyzed publicly-available gene expression
datasets of human tumors using the NextBio bioinformatics tool.
Analysis revealed a strong positive correlation between Mmp10
expression and metastatic potential in human NSCLC, colorectal
cancer, melanoma, breast cancer, renal cell carcinoma and
Figure 3. Mmp10 is critical for maintenance and growth of CMT167 oncosphere cultures. A) QPCR showing RNAi-mediated knockdown
of Mmp10 in parental CMT167 and oncosphere cultures. Relative to NT parental cells; Mean 6s.d., n=3. *p,0.0002 and **p=0.01 vs. NT parental
control. B) Effect of Mmp10 RNAi on anchorage-independent growth of parental and CMT167 oncosphere cultures. Relative to NT parental cells +/2
SEM, n=5; *p,0.05 vs, NT; **p,0.05 vs. NT parental. C) QPCR for stem cell markers in NT parental, and NT and Mmp10 RNAi CMT167 oncosphere
cells. Fold of NT parental +/2SEM, n=3; *p,0.05. D) Flow cytometry of NT and Mmp10 RNAi parental and oncosphere cells for CD133 and Notch4.
doi:10.1371/journal.pone.0035040.g003
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widespread role in human malignancy.
Discussion
A small subpopulation of self-renewing stem-like cells may be
responsible for the initiation, maintenance, progression and
metastatic spread of tumors. However, relatively little is known
Figure 4. Mmp10 is required for clonal expansion of CMT167 oncospheres. A) Photomicrographs of clonal expansion of single NT and
Mmp10 RNAi CMT167 oncosphere cells in the presence or absence or recombinant Mmp10. B) Colony diameter derived from single CMT167 NT and
Mmp10 RNAi cells. Mean +/2 SEM; n=10, *p,0.05 vs. day 1 each treatment; **p,0.05 vs. day 15 NT RNAi without Mmp10. C) Flow cytometry of NT
and Mmp10 RNAi CMT167 oncosphere cultures +/2Mmp10 for CD133 and Notch4.
doi:10.1371/journal.pone.0035040.g004
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CSCs can escape conventional chemotherapy, due to their
intrinsic drug resistance and/or relative quiescence, resulting in
disease recurrence and poor patient outcome. Therefore, thera-
peutic strategies aimed at eradicating CSCs may improve clinical
outcome of cancer patients.
Though Mmps have long been implicated in tumor progression
and metastasis, we recently demonstrated that Mmp10 is
overexpressed in human NSCLC and Kras-transformed BASC
lung cancer-initiating cells [19,20], and that Mmp10 is required
for transformed growth and invasion of human NSCLC cells in
vitro [19]. Furthermore, Mmp10
2/2 mice exhibit a significant
decrease in urethane- and Kras-induced lung tumorigenesis due to
a defect of Mmp10-deficient BASCs to expand in response to
oncogenic Kras [21]. Here, we report the surprising result that
Mmp10 promotes lung tumor initiation and metastasis through
the maintenance of a CSC-like population of lung tumor cells.
CSCs are defined by their ability to clonally expand,
differentiate into bulk tumor cells, and initiate tumors in recipient
animals. Here we show that Mmp10 is overexpressed in CSC-
enriched oncosphere cultures from two mouse lung adenocarci-
noma cell lines and is required for enhanced transformed growth
and clonal expansion in vitro, and for tumor initiation in vivo.
Inhibition of Mmp10 expression in oncospheres significantly
decreases the expression of stem cell-associated transcription
factors and cell surface markers, indicating that Mmp10 is critical
for maintaining lung CSC identity. Mmp10 expression is also
elevated in CSCs isolated from human small cell lung cancer cell
lines [27], suggesting that Mmp10 may also function in the
maintenance of these CSCs.
A key to effectively targeting NSCLC CSCs will be to accurately
identify this subpopulation within tumors. BASCs are the putative
tumor-initiating cells from which Kras-induced mouse lung tumors
originate. BASCs exhibit surface expression of Sca1, Spc and
Ccsp, however to date, human bronchioalveolar stem cells that co-
Figure 5. Tumor initiating activity of CMT167 oncosphere cultures is Mmp10 dependent. A, Orthotopic tumor growth after injection of
1,000 cells from NT adherent, NT RNAi oncosphere or Mmp10 RNAi oncosphere cultures was monitored by bioluminescence at the indicated time
points; *p,0.05 (left panel). Representative lateral views of bioluminescent images of mice bearing lung orthotopic tumors (right panel). Mmp10
function in CMT167 oncosphere tumors is cell autonomous. B) Representative bioluminescent images of NT RNAi CMT167 oncosphere orthotopic
tumors implanted into Ntg and Mmp10
2/2 recipient mice. Analysis of C) tumor size and D) metastases in Ntg or Mmp10
2/2 mice. C–D, n=10,
Mean+/2 SEM.
doi:10.1371/journal.pone.0035040.g005
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PLoS ONE | www.plosone.org 7 April 2012 | Volume 7 | Issue 4 | e35040Figure 6. Mmp10 and Notch4 expression in primary and metastatic lung tumors. Flow cytometric analysis for CD133 and Notch4
expression in CMT167 oncospheres prior to injection orthotopically into syngeneic mice (A) and CMT167 cells isolated from orthotopic tumors (B). C)
Mmp10 and Notch4 staining in a primary CMT167 oncosphere tumor (top panels) and metastatic lesion (bottom panels).
doi:10.1371/journal.pone.0035040.g006
Table 1. Mmp10 expression correlates with metastasis in human cancer types.
Tumor Type-Comparison
Fold
Change P value Reference
Colorectal Cancer-recurrent metastatic vs non metastatic cancer 2.29 0.042 [39]
Melanoma metastasis – proliferative molecular subtype vs pigmentation 9.89 0.0012 [40]
Primary breast tumor – relapse metastasis in lung vs local relapse 2.04 0.0467 [41]
NSCLC from patients with metastasis status M1 vs M0 4.4 0.025 [30]
Renal Cell Carcinoma metastasis vs primary tumor 1.46 0.0403 [42]
Colorectal Cancer -liver metastasis vs primary tumor 3.71 3.00E-15 [43]
Renal Cell Carcinoma – metastasis to lymph nodes/mediastimum vs no metastasis 2 6.00E-04 *GSE22541
Prostate Cancer -peritoneal lymph node metastasis vs primary tumor 1.8 7.20E-06 [44]
Prostate Cancer -liver metastasis vs primary tumor 1.79 0.0072 [44]
Prostate Cancer -metastatic tumor vs primary tumor 1.64 5.90E-06 [44]
Prostate Cancer -tracheal lymph node metastasis vs primary tumor 1.48 6.00E-04 [44]
doi:10.1371/journal.pone.0035040.t001
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expressed in human lung cells [28]. Interestingly, CMT167
oncosphere cultures are not only enriched in CCSP
+/SPC
+ cells
(data not shown), but also in CD133
+/Notch4
+ cells, two markers
implicated in both human and mouse CSCs from various tumor
types including lung [25,29]. Inhibition of Notch signaling blocks
the ability of glioblastoma-derived CSC neurospheres to propagate
tumors and depletes CD133
+ stem-like cells in neurospheres [29].
Likewise, Notch inhibition blocks proliferation and tumor-
initiating activity of human lung CSCs [25]. We observed
significant enrichment of Notch4
+/CD133
+ cells in CMT167
oncospheres with few single positive cells suggesting that co-
expression of these molecules is required to maintain CMT167
CSCs. Thus, Notch4 and CD133 may be useful markers of lung
CSCs across species.
Our data provide direct evidence that the role of Mmp10 in lung
CSCs is cell autonomous. Our orthotopic tumor model shows
Mmp10 staining in tumor cells but not tumor-associated stroma or
morphologically normal lung epithelium. More importantly, no
significant differences were observed in tumor number, size or
metastatic lesions formed by oncosphere cells orthotopically
injected into syngeneic Ntg or Mmp10
2/2 mice. Thus, while
many Mmps produced by tumor-associated stroma play promi-
nent roles in the invasive and metastatic properties of lung tumor
cells, Mmp10 is produced primarily by lung tumor cells to support
the autonomous growth of CSCs. Our data are consistent with
numerous reports that Mmp10 is expressed in human NSCLC
cells and not surrounding normal or tumor-associated lung tissues
[15,17,18]. Future studies will focus on determining the molecular
mechanisms that contribute to Mmp10-mediated CSC prolifera-
tion.
Poor outcome in lung cancer patients is due to metastatic
dissemination and resistance of tumor cells to chemotherapy, two
characteristics ascribed to CSCs. In primary oncosphere-derived
tumors we observed enhanced Mmp10 and Notch4 staining at the
interface between the tumor and surrounding tissue, suggesting a
role for Mmp10
+/Notch4
+ cells in tumor invasion. These data are
consistent with our previous funding that Mmp10 is required for
invasion of human NSCLC cells in vitro [19], and our current
finding that Mmp10 contributes to the metastatic behavior of
CMT167 oncosphere-derived tumors. Interestingly, tumor cells
within metastatic lesions uniformly express Mmp10 and Notch4
suggesting that they are derived from, and highly enriched in,
CSCs. Mmp10 knockdown leads to a significant reduction in
metastatic lesions indicating the importance of Mmp10 in
metastatic behavior.
Analysis of expression profiling data on NSCLC revealed a
significant correlation between Mmp10 expression and tumor
progression, local invasiveness and distant metastasis [30]. We
observed similar associations between Mmp10 expression and
metastatic behavior of human colorectal cancer, melanoma,
breast, renal and prostate cancers (Table 1). Thus, Mmp10
may play a widespread role in the metastatic behavior of many
types of human cancers. Using a bioinformatics approach, we
recently demonstrated that Mmp10 expression in human tumors is
associated with both embryonic stem cell gene signatures and
metastatic potential [21]. Interestingly, CSCs appear to promote
chemoresistance and a recent study revealed that Mmp10 is
overexpressed in cisplatin-resistant compared to cisplatin-sensitive
human ovarian adenocarcinoma cells [31]. Further studies will be
required to determine whether Mmp10 promotes metastasis and
chemoresistance in human tumor cells by maintaining a highly
metastatic, chemoresistant cancer stem cell population, as our
present data in mouse lung adenocarcinoma cells would predict.
Materials and Methods
Cell lines, enzymes, and lentiviral RNAi-mediated gene
knockdown
CMT167 and LLC cells expressing firefly luciferase were a gift
from Dr. Raphael Nemenoff (University of Colorado, Denver,
CO) and were characterized previously [32]. Briefly, these cells
were transfected with pGL3 containing firefly luciferase constitu-
tively driven by an SV40 promoter and cells expressing high
luciferase were selected using neomycin resistance [32]. Recom-
binant human proMmp10 catalytic domain was expressed in E.
coli strain BL21 (DE3), isolated from inclusion bodies, purified,
refolded, and activated in vitro by treatment with 4-aminophenyl-
mercuric acetate, essentially as described previously for Mmp3
[33]. Details of the construct and methods have been submitted for
publication elsewhere [34]. Concentrations of activated Mmp10
were determined by UV absorbance at 280 nm, using a calculated
molar extinction coefficient of 29910 M
21cm
21. Specific activity
of Mmp10 (43.75 U/mg; 1 U=100 pmol/min at 37uC) was
determined as described previously [19]. 100 U/ml of Mmp10
was added as indicated in the figure legends.
Lentiviral vectors containing short hairpin RNAi against mouse
Mmp10 were obtained from Sigma-Aldrich. A non-target control
lentiviral vector containing a short hairpin RNA construct that
does not recognize any mouse or human genes (NT) was used as a
negative control. Cells were transduced with recombinant
lentivirus and stable transfectants selected by puromycin resistance
as described previously [19]. RNAi sequences are provided in
Figure S1A. Efficiency of Mmp10 knockdown was assessed by
quantitative PCR (QPCR).
Enrichment, clonal expansion and redifferentiation of
lung CSCs
CSCs were enriched from CMT167 and LLC cells by culturing
10,000 cells/ml in serum-free DMEM-F12 medium (Gibco-
Invitrogen, Carlsbad, CA) containing 50 mg/ml insulin (Sigma-
Aldrich), 0.4% Albumin Bovine Fraction V (Sigma-Aldrich), N-2
Plus Media Supplement (R&D Systems, Minneapolis, MN), B-27
Supplement (Gibco-Invitrogen), 20 mg/ml EGF (PeproTech) and
10 mg/ml bFGF (PeproTech) (CSC medium) in ultra-low
attachment flasks (Corning, Corning, NY) to support growth of
undifferentiated oncospheres. Oncosphere cultures were expanded
by trypsinization and mechanical dissociation followed by re-
plating of single cell suspensions (10,000 cells /ml) in fresh CSC
medium. Oncospheres were collected for experiments after
2 weeks in non-adherent culture. For clonal expansion, single
cells were added to each well of 96-well ultra-low attachment tissue
culture plates (Corning) and clonal expansion was monitored at
the indicated time points. Oncosphere diameters were determined
using Image-Pro Plus 6.3 (Media Cybernetics, Bethesda, MD). To
redifferentiate oncospheres, single cell suspensions were plated in
normal growth media (10,000 cells/ml) in dishes supporting cell
attachment. Cellular proliferation was assessed by a standard
MTT assay using protocols supplied by the manufacturer
(Promega Madison, WI).
RNA isolation and quantitative PCR
Total RNA was extracted from CMT167 and LLC cells using
the RNeasy Plus Mini Kit (Qiagen, Valencia, CA). QPCR
reagents for mouse Nanog, Oct3/4, Aldh1a7, Notch1, Notch2,
Notch3, Notch4, Cd133, Bmi, Hes1, Hes2, Hey1, Hey2, Mmp 2,
7, 9, 10, 11, 12 and 14 mRNA were purchased from Applied
Biosystems (Foster City, CA). QPCR was carried out using an
Applied Biosystems 7900 thermal cycler, and data was analyzed
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Measurement of Mouse Mmp10 Protein by ELISA
Mmp10 protein in conditioned medium from CMT167
adherent or oncosphere cultures was assessed by ELISA (USCN
Life Science Inc., China). Briefly, cells were cultured for 24 hours
in fresh media prior to assay. Media were collected, separated by
centrifugation and cell number and volume of medium deter-
mined. ELISA was performed according to the manufacturer’s
instructions and results recorded at 450 nm using a SpectraMax
M5 (Molecular Devices, Sunnyvale, CA). Results are presented as
mean Mmp10 concentration per 1610
6 cells +/2 SD. Each
determination represents triplicate cultures and the results are
representative of three independent experiments.
Flow cytometry
CMT167 adherent and oncosphere cultures were disassociated
into single cells by trypsinization followed by filtration through a
40 mm cell strainer. Cells were incubated for 1 hour at 4
uC with
Alexa Fluor 488-conjugated CD133 (Millipore, Billerica, MA) and
Alexa Fluor 647 conjugated Notch4 (Biolegend, San Diego, CA)
antibodies or respective isotype controls. Cells were incubated for
1 hour at 4
uC with CCSP (Upstate, Temecula, CA) and SPC
(Santa Cruz Biotechnology, Santa Cruz, CA) antibodies followed
by a 30 minute incubation with Alexa Fluor 488– and Alexa Fluor
647 conjugated secondary antibodies (Invitrogen, Carlsbad,
California). Flow cytometry was performed on an Accuri C6 flow
cytometer and analyzed using CFlow Plus software (Accuri
Cytometers, Inc., Ann Arbor, MI).
Anchorage-independent growth and orthotopic
implantation studies
Anchorage-independent growth was assessed by seeding
CMT167 (1,000 cells/dish) or LLC (500 cells/dish) cells in soft
agar on 35 mm culture dishes and quantified after four weeks in
culture as described previously [35]. CMT167/luc cell transfec-
tants suspended in 10% Growth Factor Reduced Matrigel Matrix
(BD Biosciences) in PBS were injected orthotopically into the left
lobe of the lungs of syngeneic C57BL/6 mice using a 30-gauge
needle. For bioluminescence imaging, mice were injected
intraperitoneally with 150 mg/kg body weight luciferin prior to
sedation and imaged using the IVIS Imaging System (Caliper Life
Sciences-Xenogen, Hopkinton, MA). Biolumnescent signals were
quantified using Living Image software (Caliper Life Sciences-
Xenogen). Mouse lung tissues were prepared for histology and
immunohistochemistry as previously described [20,36]. Metastases
to the right lobes of the lung were quantitated from hematoxylin/
eosin-stained sections. Sections were stained for Mmp10 (NBP1-
03118; Novus Biologicals, Littleton, CO) and Notch4 (Santa Cruz,
Santa Cruz, CA) and antigen visualized using the Envision Plus
Dual Labeled Polymer Kit (DAKO). Images were analyzed using
the ScanScope scanner and ImageScope software (Aperio
Technologies, Vista, CA). Primary orthotopic tumors were
dissected using a dissecting scope and lung epithelial tumor cells
were isolated for CD133/Notch4 flow cytometric analysis using a
published protocol [37]. Briefly, red blood cells (RBC) were lysed
in RBC lysis buffer (StemCell Technologies) and CD45
pos and
Pecam
pos cells were removed using primary biotinylated antibodies
to CD45 (BD PharMingen) and Pecam (BD PharMingen) and the
EasySep immunomagnetic cell selection procedure (Stem Cell
Technologies). FACS analysis was carried out as described above.
All animal experiments were approved by the Institutional Animal
Care and Use Committee of Mayo Clinic (protocol #A10811).
Assessment of Mmp10 in primary human cancer datasets
The correlation between Mmp10 expression and various types
of human cancer was determined using the NextBio data mining
framework (www.nextbio.com) [38]. The degree of correlation
calculated by NextBio was based on Mmp10 values for individual
microarray studies of specific cancer types as listed in Table 1.
From these experiments, p-values and fold change measurements,
provided by NextBio, were reported.
Statistical analysis
The Student’s t test and one-way ANOVA statistical analyses
were done using SigmaStat 3.5. A P value of less than 0.05 was
considered statistically significant.
Supporting Information
Figure S1 Characterization of LLC oncospheres. A)
Phase contrast photomicrographs showing morphology of parental
adherent LLC cells (left panel), LLC cells grown as oncospheres
in stem cell culture (middle panel) and redifferentiated
oncosphere cells after return to adherent culture (right panel).
B) LLC oncosphere cultures exhibit enhanced anchorage-
independent growth. Mean fold-change from LLC parental cells
+/2SEM. n=5, *p,0.00001; **p,0.00002. C) QPCR for stem
cell markers in parental, oncosphere and redifferentiated onco-
sphere cultures. Fold of parental cells +/2SEM, n=3; *p,0.05.
(TIF)
Figure S2 Characterization of mouse lentiviral Mmp10
RNAi constructs. Lentiviral shRNA constructs targeting mouse
MMP-10 were obtained from Sigma Misssion RNAi. A) Listed are
the assigned construct #, and the target sequences of each RNAi
construct. All constructs targeted the coding sequence (CDS) of the
Mmp10 mRNA. An asterisk indicates the construct giving the
most efficient knock down of the Mmp10 mRNA, which was used
in the experiments described in the text. B) QPCR analysis of
Mmp10 mRNA abundance in NT and Mmp10 RNAi CMT167
cells. CMT167 cells were stably transduced with one of three
lentiviruses expressing an RNAi construct targeting Mmp10 or a
non-target control lentivirus as described in Materials and
Methods. Cells were harvested and analyzed by QPCR for
Mmp10 mRNA abundance. Results are expressed as % NT
control. Columns, mean; bars, SEM, n=3, (*) denotes p,0.05
relative to NT control. C) Effect of Mmp10-RNAi constructs on
anchorage-independent growth in soft agar. Results are expressed
as % NT control. Columns, mean; bars, SEM, n=5, (*) denotes
p,0.05 relative to NT control. Construct #3 was used in
subsequent experiments.
(TIF)
Figure S3 Mmp10 is critical for maintenance and
growth of LLC CSC cultures. A) QPCR showing RNAi-
mediated knockdown of Mmp10 in parental LLC and oncosphere
cultures. Relative to NT parental cell control; Mean 6s.d., n=3.
*p,0.00003 and **p,0.000001 vs. NT parental control. B) Effect
of Mmp10 RNAi on anchorage-independent growth of parental
and LLC oncosphere cultures. Relative to NT Parental cells +/2
SEM, n=5; *p,0.05 vs, NT; **p,0.05 vs. NT parental. C)
QPCR for stem cell markers in NT parental, and NT and Mmp10
RNAi LLC oncosphere cells. Fold of NT parental cells +/2SEM,
n=3; *p,0.05. D) Colony diameter of oncospheres derived from
single LLC NT and Mmp10 RNAi CSCs. Mean +/2 SEM;
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RNAi.
(TIF)
Figure S4 Mmp10 is required for stem cell gene
expression in CMT167 oncosphere cultures. A) QPCR
analysis of genes associated with stemness in CMT167 NT
oncosphere cultures, and untreated or recombinant Mmp10-
treated Mmp10 RNAi oncosphere cells. Results are expressed as
% NT oncosphere cultures. B) Mmp10-deficient CMT167
oncosphere cultures exhibit normal cell proliferation upon
redifferentiation. NT and Mmp10 RNAi CMT167 oncosphere
cultures were placed into adherent culture in the presence of
serum to induce differentiation. Cells were assessed for growth rate
by MTT assay as described in Materials and Methods. Results
represent the mean +/2 S.D.; n=5.
(TIF)
Figure S5 Mmp10 dependent tumorigenic and meta-
static activity of orthotopic CMT167 tumors. A) Ortho-
topic tumor growth was monitored by bioluminescence at the
indicated time points after injection of 100,000 NT or Mmp10
RNAi adherent CMT167 cells *p,0.05, n=10. B) Metastases in
NT RNAi adherent, and NT and Mmp10 RNAi oncosphere
tumors. *p,0.02 and **p,0.03 vs. NT adherent cell tumors.
(TIF)
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